FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1703601342> ?p ?o ?g. }

• W1703601342 abstract "Objective: To revise diagnostic criteria for neuromyelitis optica (NMO) and NMO spectrum disorders.Background: NMO is an inflammatory demyelinating CNS syndrome distinct from multiple sclerosis (MS) and associated with serum aquaporin-4 antibodies (AQP4-IgG). Current diagnostic criteria were developed in 2006 and require both optic nerve and spinal cord involvement. However, clinical and neuroimaging evidence, especially from AQP4-IgG seropositive patients, has revealed a wider disease spectrum. The International Panel for NMO Diagnosis (IPND) was convened to develop revised, evidence-based consensus diagnostic criteria.Design/Methods: The INPD met on 7 occasions between October, 2011 and November, 2013. Nineteen panel members participated in 6 working groups (clinical presentation, serology, neuroimaging, pediatrics, systemic autoimmunity, and opticospinal MS), each of which were charged with addressing focused questions to contribute to the revised diagnostic criteria. Each working group conducted systematic literature reviews related to their specific charges and summarized the results. Electronic surveys were then used to develop new criteria, which were iteratively refined through electronic scoring and face-to-face meetings.Results: The new diagnostic nomenclature defines the unified term “NMO spectrum disorders” (NMOSD), which is stratified by serological testing results (NMOSD with or without AQP4-IgG). Core characteristics of NMOSD with AQP4 antibodies include clinical syndromes and/or MRI findings related to optic nerve, spinal cord, brain stem, diencephalic, or cerebral presentations. The presence of enriched core characteristics, plus additional supportive criteria, are required for diagnosis of NMOSD without AQP4-IgG. The IPND also achieved consensus on pediatric NMOSD diagnosis, AQP4-IgG testing, monophasic NMOSD and opticospinal MS.Conclusions: The IPND achieved consensus on revised diagnostic criteria for adult and pediatric NMOSD, with or without AQP4-IgG, for clinical and research purposes and to distinguish NMOSD from competing diagnoses. These criteria require prospective validation. The proposed nomenclature allow for future revisions to account for new clinical, neuroimaging, laboratory, and antibody associations.Study Supported by: Guthy-Jackson Charitable Foundation. Disclosure: Dr. Wingerchuk has received research support from Genentech, Inc., Genzyme Corporation, Alexion, and TerumoBCT. Dr. Banwell has received personal compensation in an editorial capacity for Multiple Sclerosis and Related Disorders. Dr. Banwell9s institution has received research support from the Multiple Sclerosis Society of Canada, the Canadian Multiple Sclerosis Scientific Research Foundation, and Canadian Institute of Health Research. Dr. Bennett has received personal compensation for activities with Teva Neuroscience, Serono Inc., and Biogen Idec. Dr. Bennett has received research support from Serono Inc. Dr. Cabre has received personal compensation for activities with Biogen Idec, EMD Serono, and Novartis. Dr. Carroll has received personal compensation for activities with Bayer Pharmaceuticals Corporation, Biogen Idec, Novartis, Genzyme Corporation, Sanofi-Aventis Pharmaceuticals Inc., CSL Ltd., and Merck & Co. Inc. Dr. Carroll has received personal compensation in an editorial capacity for Multiple Sclerosis Journal. Dr. Chitnis has received personal compensation for activities with Biogen Idec, Novartis, Sanofi-Aventis Pharmaceuticals, Inc., EMD Serono, and Teva Neuroscience as a consultant. Dr. Chitnis has received research support from Merck & Co., Inc. Dr. De Seze has received personal compensation for activities with Allergan Inc., Almirall, Bayer Schering, Biogen Idec, Genzyme Corp., LFB, Merck Serono, Sanofi-Aventis Pharmaceuticals Inc., and Teva Neuroscience. Dr. Fujihara has received personal compensation for activities with Biogen Idec, Novartis, Mitsubishi Tanabe Pharma, Alexion Pharmaceutical, Chugai Pharmaceutical, Medimmune, Medical Review, Bayer Schering Pharma, Astellas Pharma, Asahi Kasei Medical, and Nihon Pharmaceutical. Dr. Fujihara has received research support from Bayer Schering Pharma, Biogen Idec Japan, Asahi Kasei Medical, the Chemo-Sero-Therapeutic Research Institute, Teva Pharmaceutical, Mitsubishi Tanabe Pharma, Teijin Pharma, Chugai Pharmaceutical, Ono Pharmaceutical, Nihon Pharmaceutical, and Genzyme Japan. Dr. Greenberg has received personal compensation for activities with Chugai, GlaxoSmithKline, Inc., Sanofi-Aventis, Diogenix, Biogen Idec, Amplimmune, Acorda, and MSAA. Dr. Greenberg has received personal compensation in an editorial capacity for JAMA Neurology. Dr. Greenberg holds stock and/or stock options in DioGenix, Inc, which sponsored research in which Dr. Greenberg was involved as an investigator. Dr. Greenberg has received research support from Guthy-Jackson Charitable Foundation, Accelerated Cure Project, and Biogen Idec. Dr. Jacob has received personal compensation for activities with Biogen Idec as a speaker. Dr. Jarius has received research support from Bayer Pharmaceuticals Corp., and Merck Serono. Dr. Lana-Peixoto has nothing to disclose. Dr. Levy has received personal compensation for activities with ApoPharma Inc. as a speaker. Dr. Levy has received research support from ApoPharma Inc. Dr. Simon has received research support from Biogen Idec. Dr. Tenembaum has received personal compensation for activities with Genzyme Corporation and Biogen Idec as a consultant, and with Bayer Schering Pharma, Teva Neuroscience, and Merck Serono as a speaker. Dr. Tenembaum has received research support from Merck Serono. Dr. Traboulsee has received personal compensation for activities with Roche Diagnostics Corp., EMD Serono, Teva Neuroscience, and Biogen Idec. Dr. Traboulsee has received research support from Bayer Pharmaceuticals Corp., and Roche Diagnostics Corp. Dr. Waters has nothing to disclose. Dr. Wellik has nothing to disclose. Dr. Weinshenker has received personal compensation for activities with Novartis, Biogen Idec, and Mitsubishi Pharmaceuticals as consultant on data safety monitoring boards; and with Elan Corporation, Ono Pharmaceutical, GlaxoSmithKline Inc., Alexion and Chugai Pharmaceuticals, and Asahi Kasei Medical Company as a consultant. Dr. Weinshenker has received royalty payments from Mayo Foundation." @default.
• W1703601342 created "2016-06-24" @default.
• W1703601342 creator A5000669492 @default.
• W1703601342 creator A5005966031 @default.
• W1703601342 creator A5008002660 @default.
• W1703601342 creator A5011213325 @default.
• W1703601342 creator A5016397545 @default.
• W1703601342 creator A5027362230 @default.
• W1703601342 creator A5030980805 @default.
• W1703601342 creator A5035890515 @default.
• W1703601342 creator A5040110913 @default.
• W1703601342 creator A5048279797 @default.
• W1703601342 creator A5051484919 @default.
• W1703601342 creator A5055725062 @default.
• W1703601342 creator A5058125590 @default.
• W1703601342 creator A5059441394 @default.
• W1703601342 creator A5068037677 @default.
• W1703601342 creator A5080221189 @default.
• W1703601342 creator A5081462122 @default.
• W1703601342 creator A5082395750 @default.
• W1703601342 creator A5082624075 @default.
• W1703601342 date "2014-04-08" @default.
• W1703601342 modified "2023-09-23" @default.
• W1703601342 title "Revised Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders (S63.001)" @default.
• W1703601342 hasPublicationYear "2014" @default.
• W1703601342 type Work @default.
• W1703601342 sameAs 1703601342 @default.
• W1703601342 citedByCount "1" @default.
• W1703601342 countsByYear W17036013422014 @default.
• W1703601342 crossrefType "journal-article" @default.
• W1703601342 hasAuthorship W1703601342A5000669492 @default.
• W1703601342 hasAuthorship W1703601342A5005966031 @default.
• W1703601342 hasAuthorship W1703601342A5008002660 @default.
• W1703601342 hasAuthorship W1703601342A5011213325 @default.
• W1703601342 hasAuthorship W1703601342A5016397545 @default.
• W1703601342 hasAuthorship W1703601342A5027362230 @default.
• W1703601342 hasAuthorship W1703601342A5030980805 @default.
• W1703601342 hasAuthorship W1703601342A5035890515 @default.
• W1703601342 hasAuthorship W1703601342A5040110913 @default.
• W1703601342 hasAuthorship W1703601342A5048279797 @default.
• W1703601342 hasAuthorship W1703601342A5051484919 @default.
• W1703601342 hasAuthorship W1703601342A5055725062 @default.
• W1703601342 hasAuthorship W1703601342A5058125590 @default.
• W1703601342 hasAuthorship W1703601342A5059441394 @default.
• W1703601342 hasAuthorship W1703601342A5068037677 @default.
• W1703601342 hasAuthorship W1703601342A5080221189 @default.
• W1703601342 hasAuthorship W1703601342A5081462122 @default.
• W1703601342 hasAuthorship W1703601342A5082395750 @default.
• W1703601342 hasAuthorship W1703601342A5082624075 @default.
• W1703601342 hasConcept C118552586 @default.
• W1703601342 hasConcept C142724271 @default.
• W1703601342 hasConcept C15755913 @default.
• W1703601342 hasConcept C159654299 @default.
• W1703601342 hasConcept C187212893 @default.
• W1703601342 hasConcept C187382586 @default.
• W1703601342 hasConcept C203014093 @default.
• W1703601342 hasConcept C2777154362 @default.
• W1703601342 hasConcept C2779328510 @default.
• W1703601342 hasConcept C2780640218 @default.
• W1703601342 hasConcept C2781137167 @default.
• W1703601342 hasConcept C2908708501 @default.
• W1703601342 hasConcept C45189115 @default.
• W1703601342 hasConcept C58693492 @default.
• W1703601342 hasConcept C71924100 @default.
• W1703601342 hasConceptScore W1703601342C118552586 @default.
• W1703601342 hasConceptScore W1703601342C142724271 @default.
• W1703601342 hasConceptScore W1703601342C15755913 @default.
• W1703601342 hasConceptScore W1703601342C159654299 @default.
• W1703601342 hasConceptScore W1703601342C187212893 @default.
• W1703601342 hasConceptScore W1703601342C187382586 @default.
• W1703601342 hasConceptScore W1703601342C203014093 @default.
• W1703601342 hasConceptScore W1703601342C2777154362 @default.
• W1703601342 hasConceptScore W1703601342C2779328510 @default.
• W1703601342 hasConceptScore W1703601342C2780640218 @default.
• W1703601342 hasConceptScore W1703601342C2781137167 @default.
• W1703601342 hasConceptScore W1703601342C2908708501 @default.
• W1703601342 hasConceptScore W1703601342C45189115 @default.
• W1703601342 hasConceptScore W1703601342C58693492 @default.
• W1703601342 hasConceptScore W1703601342C71924100 @default.
• W1703601342 hasOpenAccess W1703601342 @default.
• W1703601342 hasRelatedWork W1577289485 @default.
• W1703601342 hasRelatedWork W1779352265 @default.
• W1703601342 hasRelatedWork W1836182162 @default.
• W1703601342 hasRelatedWork W1968741714 @default.
• W1703601342 hasRelatedWork W2004839802 @default.
• W1703601342 hasRelatedWork W2029259703 @default.
• W1703601342 hasRelatedWork W2076863510 @default.
• W1703601342 hasRelatedWork W2120238028 @default.
• W1703601342 hasRelatedWork W2128674184 @default.
• W1703601342 hasRelatedWork W2136132690 @default.
• W1703601342 hasRelatedWork W2266546919 @default.
• W1703601342 hasRelatedWork W2315357470 @default.
• W1703601342 hasRelatedWork W2317419576 @default.
• W1703601342 hasRelatedWork W2331764873 @default.
• W1703601342 hasRelatedWork W2538779678 @default.
• W1703601342 hasRelatedWork W2550942528 @default.
• W1703601342 hasRelatedWork W2591291050 @default.
• W1703601342 hasRelatedWork W2749646834 @default.
• W1703601342 hasRelatedWork W2752191590 @default.
• W1703601342 hasRelatedWork W67148232 @default.

• next